CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 200 target
Drug / intervention
Therapeutic 4SCAR19 cellsgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03050190
NCT03050190Phase 1RecruitingOn Track
CompareCT.gov

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

Shenzhen Geno-Immune Medical Institute·interventional·Posted Feb 10, 2017·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating Therapeutic 4SCAR19 cells for B-cell Malignancies. Currently recruiting, targeting 200 participants across 1 site.

Detailed Summary

The study will evaluate safety and efficacy of a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Malignancies
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20172018201920202021202220232024202520262027202820292030
First PostedFeb 10, 2017
Enrollment StartMay 1, 2025
Primary CompletionSep 1, 2028
Study CompletionDec 31, 2029
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 9.4 years agoPrimary completion in 2.2 years

Arms & Interventions

Therapeutic 4SCAR19 cellsexperimental

Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.

Genetic: Therapeutic 4SCAR19 cells

Interventions

Therapeutic 4SCAR19 cellsgenetic

Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19